文献速递自身免疫性与大疱性皮肤病

高通量蛋白组学揭示大疱性类天疱疮的分子聚类与严重度生物标志物

High-throughput proteomics uncovers molecular clusters and biomarkers of severity in bullous pemphigoid.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-12-14

该研究用Olink靶向96炎症蛋白面板分析大疱性类天疱疮(BP)患者皮肤活检和 matched 血清及健康对照,发现CCL13在皮肤和血清中均显著升高且与疾病活动度评分和自身抗体滴度强相关,并识别出两个皮肤分子聚类,提示BP存在生物学异质性。

要点

  • 皮肤CCL13水平与BP疾病活动度指数评分及自身抗体滴度强相关。
  • BP皮肤存在两个蛋白组学聚类,其中一聚类以2型炎症为主且BP180-IgG滴度更高。
  • 基线血清IL22RA1较高者与1年随访治疗无应答相关。

核心结论

  • CCL13是BP中最突出的炎症蛋白之一,两个皮肤蛋白组学聚类提示BP存在生物学异质性,支持内型驱动的个体化治疗策略。

研究设计与样本

  • 研究纳入29例BP患者皮肤活检和27份匹配血清及14例健康对照,用Olink Target 96 Inflammation面板分析,并与公共单细胞转录组数据比较验证。

主要发现

  • BP皮肤和血清分别有22和16个差异表达蛋白;CCL13、IL-6、OSM、TNFSF14和CCL19在皮肤和血清中均显著升高。
  • 皮肤CCL13主要由角质形成细胞表达,与BP疾病活动度指数评分和自身抗体滴度强相关,是聚类分离的主要驱动因素。
  • 两个皮肤分子聚类中,一个显示更广泛的以2型炎症为主的激活且BP180-IgG抗体滴度显著更高。
  • 基线血清IL22RA1水平较高见于1年随访无应答患者。
  • 蛋白组学发现与公共BP皮损单细胞RNA测序转录组数据高度一致。

临床怎么用

  • CCL13和IL22RA1等蛋白可能有助于未来对BP患者进行更精确分类并指导个体化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bullous pemphigoid is a chronic autoimmune blistering disease characterized by subepidermal blisters and caused by autoantibodies against BP180 and BP230. Although type 2 inflammation is considered relevant to its pathogenesis, the full spectrum of immune dysregulation in BP remains incompletely defined. OBJECTIVES: To comprehensively profile local and systemic inflammatory responses in BP and explore their potential associations with disease severity, clinical features and treatment outcomes. METHODS: A total of 29 skin biopsies and 27 matched serum samples from patients with bullous pemphigoid, along with samples from 14 healthy controls, were analysed using the Olink Target 96 Inflammation panel. Analyses included principal component analysis, unsupervised clustering, differential expression, gene set enrichment and k-means clustering to define molecular subgroups. Proteomic data were further compared with a publicly available single-cell transcriptomic dataset from bullous pemphigoid skin for external validation. RESULTS: Proteomic analysis revealed distinct inflammatory signatures in bullous pemphigoid skin and sera compared to controls, with 22 and 16 differentially expressed proteins, respectively. CCL13, IL-6, OSM, TNFSF14 and CCL19 were significantly elevated in both compartments. Cutaneous CCL13, expressed mainly by keratinocytes, strongly correlated with the bullous pemphigoid disease activity index score and autoantibody titres. Two molecular skin clusters were identified, with one showing broader, predominantly type 2 inflammatory activation and significantly higher titres of BP180-IgG antibodies. CCL13 was a major driver of cluster separation. Higher baseline serum IL22RA1 levels were observed in non-responder patients at 1-year follow-up. Proteomic findings showed high concordance with transcriptomic data derived from publicly available single-cell RNA sequencing of bullous pemphigoid lesional skin. CONCLUSIONS: CCL13 was among the most prominent inflammatory proteins identified in bullous pemphigoid. The emergence of two distinct skin proteomic clusters highlights a biological heterogeneity of bullous pemphigoid, indicating the need for endotype-driven, personalized treatment strategies. UNLABELLED: WHAT IS THE DISEASE?: Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease. It usually affects older adults and causes severe itching, redness and blisters that can greatly reduce quality of life. LOCATION OF THE STUDY: This study was carried out in Italy at the Universities of Siena and Florence. AIM OF THE STUDY: We aimed to better understand the inflammatory profile of BP and to identify proteins linked to disease severity or treatment response. METHODOLOGY: We analysed skin biopsies and blood samples from 30 patients with BP and 14 healthy controls. Proteins were measured using a high‐throughput technology called Olink, which can detect many inflammation‐related proteins simultaneously. KEY FINDINGS: We found that a protein called CCL13 was strongly increased in the skin and blood of patients with BP. Higher levels of CCL13 in the skin were linked to more severe disease and higher levels of the autoantibodies causing BP. We also observed two different groups of patients based on their skin protein patterns: one with lower and one with higher inflammatory activity. In the blood, additional proteins were identified that were associated with poor treatment response. CONCLUSIONS AND PRACTICAL IMPLICATIONS: This study shows that BP is not identical in all patients. Proteins such as CCL13 and IL‐22RA1 were associated with disease severity and treatment outcomes, and may in the future help doctors classify patients more precisely and guide personalized treatment.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Calabrese L, Vallini G, Bonacchi L, et al. High-throughput proteomics uncovers molecular clusters and biomarkers of severity in bullous pemphigoid. J Eur Acad Dermatol Venereol. 2025. PMID: 41392513. doi:10.1111/jdv.70252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。